HAMLET Pharma AB is a pharmaceutical company with strong links to research, working with natural and biological substances. The discovery of HAMLET defines a new class of cancer drugs with broad effects against cancers of different origin and a high degree of selectivity. (Human Alpha-lactalbumin Made LEthal to Tumor cells) HAMLET is a tumoricidal protein-lipid complex, formed by two GRAS (generally regarded as safe) molecules present in human milk. The novel therapeutic entity HAMLET is formed when the human milk protein alpha-lactalbumin undergoes a conformational change and binds to oleic acid. Advanced technologies allow us to see molecules, measure them from every angle, and understand their deepest secrets. Using such techniques, we were able to identify the structure of HAMLET and especially the domains that are responsible for the killing effect. This is how we identified the Alpha1 peptide, which forms a lipid complex and kills tumor cells. This smaller part of the HAMLET molecule can be produced synthetically, and used as a drug candidate. Development focuses on drugs, which will be used primarily for the treatment and prevention of cancer. HAMLET kills tumor cells, and has proven safe in proof-of-concept studies in animal models. HAMLET has shown a therapeutic effect on skin papillomas in a placebo-controlled clinical trial and injection of HAMLET into the bladders of patients with bladder cancer has caused the shedding of dead cancer cells. Phase I/II clinical trials in human patients with bladder cancer are currently underway. HAMLET is a registered trademark of HAMLET Pharma.